{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:50:23Z","timestamp":1782190223595,"version":"3.54.5"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Reduced-intensity conditioning (RIC) has expanded the use of allogeneic hematopoietic transplant (allo-HCT) as a potentially curative treatment of a variety of hematological cancers including acute myeloid leukemia (AML) by reducing treatment-related morbidity and mortality. However, the RIC allo HCT success is limited by relapse, especially for patients with adverse molecular\/cytogenetics or with measurable residual disease (MRD) at the time of HCT. Radioimmunotherapy (RIT) potentially improves the efficacy of RIC by enhancing the cytoreductive effect with the ability to deliver targeted radiation to sites of hematopoietic malignancy while sparing nonhematopoietic organs. In clinical trials using different combinations of targeting antibodies and radionuclides, reliable radiation targeting to marrow and spleen has been consistently demonstrated. Toxicity is often predictable and organ-specific with hepatic toxicity most commonly limiting the therapeutic dose. In this article, we review the rationale for combining RIT with RIC and discuss antigen selection and distinct properties of \u03b2- and \u03b1-emitting radionuclides. We also summarize clinical experience combining fludarabine-based RIC regimens with RIT and provide emerging directions, including the development of \u03b1-emitter platforms. Available data suggest that RIT may potentially improve disease control while maintaining the tolerability of RIC. Because the majority of the current evidence involves early-phase studies, additional prospective evaluation is needed before radioimmunotherapy can be considered a standard component of conditioning.<\/jats:p>","DOI":"10.3389\/fonc.2026.1846420","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:32:09Z","timestamp":1782189129000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Radioimmunotherapy as a targeted strategy of reduced-intensity conditioning for allogeneic transplantation in leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Phuong T.","family":"Vo","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutch Cancer Center","place":["Seattle, WA, United States"]},{"name":"Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnnie J.","family":"Orozco","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine","place":["Seattle, WA, United States"]},{"name":"Translational Science & Therapeutics Division, Fred Hutch Cancer Center","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine","place":["Seattle, WA, United States"]},{"name":"Translational Science & Therapeutics Division, Fred Hutch Cancer Center","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/35077251","article-title":"Haematopoietic cell transplantation as immunotherapy","volume":"411","author":"Appelbaum","year":"2001","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic Malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v126.23.2571.2571","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024247","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old","volume":"145","author":"Walter","year":"2025","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.4.1237","article-title":"Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome","volume":"94","author":"Matthews","year":"1999","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2317","article-title":"131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission","volume":"107","author":"Pagel","year":"2006","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v83.5.1390.1390","article-title":"Retention of B-cell-specific monoclonal antibodies by human lymphoma cells","volume":"83","author":"Press","year":"1994","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.014","article-title":"Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome","volume":"20","author":"Mawad","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0043-1","article-title":"Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia","volume":"87","author":"Koenecke","year":"2008","journal-title":"Int J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.229492","article-title":"Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed\/refractory leukemia or myelodysplasia","volume":"105","author":"Vo","year":"2020","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.160","article-title":"Clinical radioimmunotherapy--the role of radiobiology","volume":"8","author":"Pouget","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000151932","article-title":"The biology of CD45 and its use as a therapeutic target","volume":"45","author":"Dahlke","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08025.x","article-title":"188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation","volume":"148","author":"Lauter","year":"2010","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2015.10.007","article-title":"Radioimmunotherapy for treatment of acute leukemia","volume":"46","author":"Bodet-Milin","year":"2016","journal-title":"Semin Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.14694\/edbook_am.2014.34.e126","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia","volume":"16","author":"Rosenblat","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B21","article-title":"Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry","volume":"40","author":"Nikula","year":"1999","journal-title":"J Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2060735","article-title":"Where do we stand with radioimmunotherapy for acute myeloid leukemia","volume":"22","author":"Walter","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-16-2523","article-title":"Whither radioimmunotherapy: to be or not to be","volume":"77","author":"Green","year":"2017","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-467035","article-title":"Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model","volume":"121","author":"Orozco","year":"2013","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-08-4363","article-title":"Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211","volume":"69","author":"Nakamae","year":"2009","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347039","article-title":"Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model","volume":"118","author":"Pagel","year":"2011","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4161\/chim.20726","article-title":"Conditioning with alpha-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation","volume":"3","author":"Kornblit","year":"2012","journal-title":"Chimerism"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/S2666-6367(21)00083-X","article-title":"First-in-human astatine-211\u2013BC8-B10 combined with fludarabine and total body irradiation conditioning: a dose-escalation study","volume":"27","author":"Sandmaier","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B29","article-title":"High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model","volume":"59","author":"Behr","year":"1999","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.12.003","article-title":"Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting alpha-particles or Auger electrons","volume":"109","author":"Aghevlian","year":"2017","journal-title":"Adv Drug Delivery Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13060906","article-title":"Overview of the most promising radionuclides for targeted alpha therapy: the \"Hopeful Eight","volume":"13","author":"Eychenne","year":"2021","journal-title":"Pharmaceutics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nchem.1580","article-title":"Enigmatic astatine","volume":"5","author":"Wilbur","year":"2013","journal-title":"Nat Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01580-7","article-title":"Development of [(211)At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ Malignancies","volume":"36","author":"Laszlo","year":"2022","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v77.8.1660.bloodjournal7781660","article-title":"Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens","volume":"77","author":"Clift","year":"1991","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v92.4.1455.spll2_1455_1456","article-title":"Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia","volume":"92","author":"Clift","year":"1998","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.11.3960a.423a43g_3960_3962","article-title":"Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia","volume":"94","author":"Clift","year":"1999","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01801","article-title":"Graft versus leukemia: current status and future perspectives","volume":"39","author":"O'Neill","year":"2021","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017065","article-title":"The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy","volume":"10","author":"Hagen","year":"2026","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-617019","article-title":"Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment","volume":"127","author":"Orozco","year":"2016","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380436","article-title":"Durable donor engraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1089\/hum.2015.021","article-title":"(211)Astatine-conjugated monoclonal CD45 antibody-based nonmyeloablative conditioning for stem cell gene therapy","volume":"26","author":"Burtner","year":"2015","journal-title":"Hum Gene Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.162388","article-title":"Alpha-imaging confirmed efficient targeting of CD45-positive cells after 211At-radioimmunotherapy for hematopoietic cell transplantation","volume":"56","author":"Frost","year":"2015","journal-title":"J Nucl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.02.018","article-title":"Addition of astatine-211-labeled anti-CD45 antibody to TBI as conditioning for DLA-identical marrow transplantation: a novel strategy to overcome graft rejection in a canine presensitization model: \"Radioimmunotherapy to overcome transfusion-induced sensitization","volume":"27","author":"Nakaya","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267540","article-title":"(211)At-labeled anti-CD45 antibody as a nonmyeloablative conditioning for canine DLA-haploidentical stem cell transplantation","volume":"65","author":"Frost","year":"2024","journal-title":"J Nucl Med"},{"key":"B46","article-title":"Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias","volume":"55","author":"Jurcic","year":"1995","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02018","article-title":"Randomized phase III SIERRA trial of (131)I-apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed\/refractory AML","volume":"43","author":"Gyurkocza","year":"2025","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.174","article-title":"131I-apamistamab-led allogeneic hematopoietic cell transplant for patients with TP53 mutated R\/R AML results in significantly improved outcomes","volume":"30","author":"Foran","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3712","article-title":"Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator actinium-225-lintuzumab","volume":"28","author":"Rosenblat","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B50","article-title":"A phase 2 study of actinium-225 (\u00b2\u00b2\u2075Ac)-lintuzumab in older patients with untreated acute myeloid leukemia (AML)","volume-title":"Blood","author":"Finn","year":"2017"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091358","article-title":"Cd123 as a therapeutic target in the treatment of hematological Malignancies","volume":"11","author":"Testa","year":"2019","journal-title":"Cancers Bsl"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.033","article-title":"Efficacy and safety of anti-cd45-saporin as conditioning agent for rag deficiency","volume":"147","author":"Castiello","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010561","article-title":"Clearing and replacing tissue-resident myeloid cells with an anti-cd45 antibody-drug conjugate","volume":"7","author":"Gustafsson","year":"2023","journal-title":"Blood Adv"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.02.001","article-title":"Effective multi-lineage engraftment in a mouse model of fanconi anemia using non-genotoxic antibody-based conditioning","volume":"17","author":"Srikanthan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/jci145501","article-title":"Antibody-drug conjugates plus janus kinase inhibitors enable mhc-mismatched allogeneic hematopoietic stem cell transplantation","volume":"131","author":"Persaud","year":"2021","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1846420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:32:19Z","timestamp":1782189139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1846420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":55,"alternative-id":["10.3389\/fonc.2026.1846420"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1846420","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1846420"}}